This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Takuma Katayama: Innovator in Pharmaceutical Composition
Introduction
Takuma Katayama is a notable inventor based in Kobe, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patent.
Latest Patents
Katayama holds a patent for a pharmaceutical composition and dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide. This invention relates to pharmaceutical compositions that include this compound as an active ingredient, specifically focusing on its hydrochloride form. The patent outlines the preparation methods, therapeutic uses, and dosage forms of this pharmaceutical composition.
Career Highlights
He is currently associated with Boehringer Ingelheim International GmbH, where he continues to advance his research and development efforts in the pharmaceutical industry. His work has contributed to the development of new therapeutic treatments.
Collaborations
Katayama has collaborated with notable colleagues, including Kenji Egusa and Kazutoshi Yokoyama, enhancing the innovative capacity of his projects.
Conclusion
Takuma Katayama's contributions to pharmaceutical innovations exemplify the impact of dedicated research and collaboration in advancing medical science. His patent reflects a commitment to improving therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile